Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Huprine X is a Novel High-Affinity Inhibitor of Acetylcholinesterase That Is of Interest for Treatment of Alzheimer's Disease

Pelayo Camps, Bernadette Cusack, William D. Mallender, Rachid El Achab, Jordi Morral, Diego Muñoz-Torrero and Terrone L. Rosenberry
Molecular Pharmacology February 2000, 57 (2) 409-417;
Pelayo Camps
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernadette Cusack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William D. Mallender
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachid El Achab
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Morral
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego Muñoz-Torrero
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terrone L. Rosenberry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Inhibitors of the enzyme acetylcholinesterase (AChE) slow and sometimes reverse the cognitive decline experienced by individuals with Alzheimer's disease. Huperzine A, a natural product used in traditional Chinese herbal medicine, and tacrine (Cognex) are among the potent AChE inhibitors used in this treatment, but the search for more selective inhibitors continues. We report herein the synthesis and characterization of (−)-12-amino-3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinoline hydrochloride (huprine X), a hybrid that combines the carbobicyclic substructure of huperzine A with the 4-aminoquinoline substructure of tacrine. Huprine X inhibited human AChE with an inhibition constantK I of 26 pM, indicating that it binds to this enzyme with one of the highest affinities yet reported. Under equivalent assay conditions, this affinity was 180 times that of huperzine A, 1200 times that of tacrine, and 40 times that of E2020 (donepezil, Aricept), the most selective AChE inhibitor currently approved for therapeutic use. The association and dissociation rate constants for huprine X with AChE were determined, and the location of its binding site on the enzyme was probed in competition studies with the peripheral site inhibitor propidium and the acylation site inhibitor edrophonium. Huprine X showed no detectable affinity for the edrophonium-AChE complex. In contrast, huprine X did form a ternary complex with propidium and AChE, although its affinity for the free enzyme was found to be 17 times its affinity for the propidium-AChE complex. These data indicated that huprine X binds to the enzyme acylation site in the active site gorge but interferes slightly with the binding of peripheral site ligands.

Footnotes

  • Send reprint requests to: Terrone L. Rosenberry, Department of Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Rd., Jacksonville, FL 32224. E-mail:rosenb{at}mayo.edu

  • ↵1 Throughout this paper, we number residues according to the TcAChE sequence. For example, W84 and S200 in this sequence correspond to W86 and S203, respectively, in mammalian AChE.

  • ↵2 One unit of AChE activity corresponds to 1 μmol of acetylthiocholine hydrolyzed per minute under standard pH-stat assay conditions, and these conditions correspond to maximal AChE activity at pH 8 (Rosenberry and Scoggin, 1984). Our conventional spectrophotometric assay at 412 nm is conducted in pH 7 buffer with 0.5 mM acetylthiocholine, conditions that result in 4.5 ΔA412 nm/min with 1 nM AChE or ∼76% of the maximal activity.

  • ↵4 See the Physicians' Desk Reference (1999), Medical Economics Co., Montvale, New Jersey.

  • ↵3 The K I determined for TMTFA (50 pM; Szegletes et al., 1998) was based on the total concentration of TMTFA and its hydrate in solution. Because the hydrate is not an AChE inhibitor but is present in 105-fold excess over TMTFA (Nair et al., 1993), the intrinsic equilibrium dissociation constant K D for TMTFA itself with AChE is about 10−15 M.

  • This work was supported by Grant NS-16577 from the National Institutes of Health, DAMD 17-98-2-8019 from the U.S. Army Medical Research Acquisition Activity, and by grants from the Muscular Dystrophy Association of America. Financial support from the Comisión Interministerial de Ciencia y Tecnologı́a (Programa Nacional de Tecnologı́a de los Procesos Quı́micos, Project QUI96–0828), Fundació “La Marató de TV3” (Project 3004/97), Comissionat per a Universitats i Recerca of the Generalitat de Catalunya (Project 1997-SGR-00140), and Medichem, S.A., and fellowships from Comissió Interdepartamental de Recerca i InnovacióTecnològica of the Generalitat de Catalunya to J. Morral and from Agencia Española de Cooperación Internacional (Instituto de Cooperación con el Mundo Arabe, Mediterráneo y Paı́ses en Desarrollo) to R.E.A. are gratefully acknowledged.

  • Abbreviations:
    AChE
    acetylcholinesterase
    MPLC
    medium-pressure liquid chromatography
    DTNB
    5,5′-dithiobis-(2-nitrobenzoic acid)
    TcAChE
    Torpedo californica acetylcholinesterase
    TMTFA
    m-(N, N,Ntrimethylammonio)trifluoroacetophenone
    COSY
    correlation spectroscopy
    HMQC
    heteronuclear multiple-quantum coherence
    • Received August 23, 1999.
    • Accepted November 3, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 57 (2)
Molecular Pharmacology
Vol. 57, Issue 2
1 Feb 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Huprine X is a Novel High-Affinity Inhibitor of Acetylcholinesterase That Is of Interest for Treatment of Alzheimer's Disease
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Huprine X is a Novel High-Affinity Inhibitor of Acetylcholinesterase That Is of Interest for Treatment of Alzheimer's Disease

Pelayo Camps, Bernadette Cusack, William D. Mallender, Rachid El Achab, Jordi Morral, Diego Muñoz-Torrero and Terrone L. Rosenberry
Molecular Pharmacology February 1, 2000, 57 (2) 409-417;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Huprine X is a Novel High-Affinity Inhibitor of Acetylcholinesterase That Is of Interest for Treatment of Alzheimer's Disease

Pelayo Camps, Bernadette Cusack, William D. Mallender, Rachid El Achab, Jordi Morral, Diego Muñoz-Torrero and Terrone L. Rosenberry
Molecular Pharmacology February 1, 2000, 57 (2) 409-417;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Michaelis Menten quantification of GPCR-G protein signalling
  • Human mAb 3F1 targeting the fuctional epitopes of Siglec-15
  • The regulation and mechanisms of ImKTX58 on KV1.3 channel
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics